{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.60","upperLimit":"95.94","value":"89.77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"}],"units":"Participants"}],"description":"DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Consolidation (4 w): vincristine (VIN) d1; MP d1-28; IT methotrexate (MTX) d1/8/15; leucovorin (LV) d3-4/10-11/17-18 Interim maintenance I (8 wks): VIN \\& IV MTX d1/11/21/31/41; IT MTX d31; LV d36-34 Delayed-intensification (8 wks): Patients receive dexamethasone (DEX) d1-7/15-21; VIN \\& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/33-39; IT MTX d1/29; and LV d3-4/31-32 Interim maintenance II (8 wks): VIN \\& IV MTX d1/11/21/31/41; IT MTX d1/31; and LV d3-4/33-34 Maintenance: VIN d1; DEX d1-5; PO MTX wkly d8-78; MP d1-84; and IT MTX d1. Courses repeat every 12 wks for 2 years (timed from the start of interim maintenance I therapy).","id":"OG000","title":"Standard Risk With Down Syndrome"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5.1 years","title":"DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care","type":"PRIMARY","unitOfMeasure":"percent probability"}